Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib

BACKGROUND AND AIMS: Response to sorafenib is highly variable in hepatocellular carcinoma (HCC). Baseline inflammatory parameters and treatment toxicities may improve survival prediction in patients on sorafenib therapy. RESULTS: 442 patients with advanced stage HCC on sorafenib were recruited (foll...

Descripción completa

Detalles Bibliográficos
Autores principales: Howell, Jessica A., Pinato, David J., Ramaswami, Ramya, Arizumi, Tadaaki, Ferrari, Carlotta, Gibbin, Antonello, Burlone, Michela E., Guaschino, Giulia, Toniutto, Pierluigi, Black, James, Sellers, Laura, Kudo, Masatoshi, Pirisi, Mario, Sharma, Rohini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482646/
https://www.ncbi.nlm.nih.gov/pubmed/28212535
http://dx.doi.org/10.18632/oncotarget.15322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482646/
https://www.ncbi.nlm.nih.gov/pubmed/28212535
http://dx.doi.org/10.18632/oncotarget.15322

Ejemplares similares